Caroline Bodet-Milin1, Alain Faivre-Chauvet2, Thomas Carlier2, Catherine Ansquer2, Aurore Rauscher3, Eric Frampas2,3,4, Frederique Toulgoat4, Damien Masson5, Mickael Bourgeois2, Evelyne Cerato6, Vincent Rohmer7, Olivier Couturier8, Delphine Drui9, David M Goldenberg10, Robert M Sharkey11, Jacques Barbet12, Francoise Kraeber-Bodere2. 1. Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France; caroline.milin@chu-nantes.fr. 2. Université de Nantes, CHU Nantes, CNRS, INSERM, CRCINA, Nantes, France. 3. Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France. 4. Radiology Department, University Hospital, Nantes, France. 5. Biology Department, University Hospital, Nantes, France. 6. Délégation à la Recherche Clinique et à l'Innovation, University Hospital, Nantes, France. 7. Endocrinology Department, University Hospital, Angers, France. 8. Nuclear Medicine Department, University Hospital, Angers, France. 9. Endocrinology Department, University Hospital, Nantes, France. 10. IBC Pharmaceuticals, Inc., Morris Plains, New Jersey. 11. Immunomedics, Inc., Morris Plains, New Jersey; and. 12. GIP Arronax, Saint-Herblain, France.
Abstract
Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68Ga-labeled IMP288 peptide for immuno-PET have been optimized in a first-in-humans study performed on medullary thyroid carcinoma (MTC) patients (the iPET-MTC study). The aim of this post hoc analysis was to determine the sensitivity of immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18F-l-dihydroxyphenylalanine (18F-DOPA) PET/CT. Methods: Twenty-five studies were analyzed in 22 patients. All patients underwent immuno-PET 1 and 2 h after 68Ga-IMP288 injection pretargeted by TF2, in addition to neck, thoracic, abdominal, and pelvic CT; bone and liver MRI; and 18F-DOPA PET/CT. The gold standard was histology or confirmation by one other imaging method or by imaging follow-up. Results: In total, 190 lesions were confirmed by the gold standard: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous tissue, heart, brain, and pancreas). The number of abnormal foci detected by immuno-PET was 210. Among these, 174 (83%) were confirmed as true-positive by the gold standard. Immuno-PET showed a higher overall sensitivity (92%) than 18F-DOPA PET/CT (65%). Regarding metastatic sites, immuno-PET had a higher sensitivity than CT, 18F-DOPA PET/CT, or MRI for lymph nodes (98% vs. 83% for CT and 70% for 18F-DOPA PET/CT), liver (98% vs. 87% for CT, 65% for 18F-DOPA PET/CT, and 89% for MRI), and bone (92% vs. 64% for 18F-DOPA PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs. 100% for CT and 14% for 18F-DOPA PET/CT). Tumor SUVmax at 60 min ranged from 1.2 to 59.0, with intra- and interpatient variability. Conclusion: This post hoc study demonstrates that anti-carcinoembryonic antigen immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than 18F-DOPA PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.
Pretargeting parameters for the use of anti-carcinoembryonic antigen (CEA) bispecific monoclonal antibody TF2 and the 68Ga-labeled IMP288 peptide for immuno-PET have been optimized in a first-in-humans study performed on medullary thyroid carcinoma (MTC) patients (the iPET-MTC study). The aim of this post hoc analysis was to determine the sensitivity of immuno-PET in relapsing MTC patients, in comparison with conventional imaging and 18F-l-dihydroxyphenylalanine (18F-DOPA) PET/CT. Methods: Twenty-five studies were analyzed in 22 patients. All patients underwent immuno-PET 1 and 2 h after 68Ga-IMP288 injection pretargeted by TF2, in addition to neck, thoracic, abdominal, and pelvic CT; bone and liver MRI; and 18F-DOPA PET/CT. The gold standard was histology or confirmation by one other imaging method or by imaging follow-up. Results: In total, 190 lesions were confirmed by the gold standard: 89 in lymph nodes, 14 in lungs, 46 in liver, 37 in bone, and 4 in other sites (subcutaneous tissue, heart, brain, and pancreas). The number of abnormal foci detected by immuno-PET was 210. Among these, 174 (83%) were confirmed as true-positive by the gold standard. Immuno-PET showed a higher overall sensitivity (92%) than 18F-DOPA PET/CT (65%). Regarding metastatic sites, immuno-PET had a higher sensitivity than CT, 18F-DOPA PET/CT, or MRI for lymph nodes (98% vs. 83% for CT and 70% for 18F-DOPA PET/CT), liver (98% vs. 87% for CT, 65% for 18F-DOPA PET/CT, and 89% for MRI), and bone (92% vs. 64% for 18F-DOPA PET/CT and 86% for MRI), whereas sensitivity was lower for lung metastases (29% vs. 100% for CT and 14% for 18F-DOPA PET/CT). Tumor SUVmax at 60 min ranged from 1.2 to 59.0, with intra- and interpatient variability. Conclusion: This post hoc study demonstrates that anti-carcinoembryonic antigen immuno-PET is an effective procedure for detecting metastatic MTC lesions. Immuno-PET showed a higher overall sensitivity than 18F-DOPA PET/CT for disclosing metastases, except for the lung, where CT remains the most effective examination.
Authors: Giorgio Treglia; Fabrizio Cocciolillo; Francesco Di Nardo; Andrea Poscia; Chiara de Waure; Alessandro Giordano; Vittoria Rufini Journal: Acad Radiol Date: 2012-07-20 Impact factor: 3.173
Authors: Efrat Dotan; Steven J Cohen; Alexander N Starodub; Christopher H Lieu; Wells A Messersmith; Pamela S Simpson; Michael J Guarino; John L Marshall; Richard M Goldberg; J Randolph Hecht; William A Wegener; Robert M Sharkey; Serengulam V Govindan; David M Goldenberg; Jordan D Berlin Journal: J Clin Oncol Date: 2017-08-17 Impact factor: 44.544
Authors: William J McBride; Robert M Sharkey; Habibe Karacay; Christopher A D'Souza; Edmund A Rossi; Peter Laverman; Chien-Hsing Chang; Otto C Boerman; David M Goldenberg Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: P Peltier; C Curtet; J F Chatal; J M Le Doussal; G Daniel; G Aillet; A Gruaz-Guyon; J Barbet; M Delaage Journal: J Nucl Med Date: 1993-08 Impact factor: 10.057
Authors: J Barbet; P Peltier; S Bardet; J P Vuillez; I Bachelot; S Denet; P Olivier; F Leccia; B Corcuff; D Huglo; C Proye; E Rouvier; P Meyer; J F Chatal Journal: J Nucl Med Date: 1998-07 Impact factor: 10.057
Authors: Caroline Bodet-Milin; Ludovic Ferrer; Aurore Rauscher; Damien Masson; Latifa Rbah-Vidal; Alain Faivre-Chauvet; Evelyne Cerato; Caroline Rousseau; José Hureaux; Olivier Couturier; Pierre-Yves Salaün; David M Goldenberg; Robert M Sharkey; Françoise Kraeber-Bodéré; Jacques Barbet Journal: Front Med (Lausanne) Date: 2015-11-27